Back to Stock Dashboard
Sector:
Healthcare
Add to portfolio
ZBIO
Zenas BioPharma, Inc.
Zenas BioPharma, Inc. (ZBIO) is rated C+ (2.7/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (B+); its weakest is Value (C-).
Quantitative Factor Evaluation • Updated
Overall Rating
2.7
/ 5.0
C+
Value
C-
Factor Score
1.9
/ 5.0
Growth
B+
Factor Score
3.5
/ 5.0
Profitability
C
Factor Score
2.2
/ 5.0
Momentum
B
Factor Score
3.2
/ 5.0
Revisions
C+
Factor Score
2.6
/ 5.0
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
P/E Ratio
-5.8
EV / EBITDA
-5.3
Rev Growth YoY
N/A
Gross Margin
0.0%
Price Return 3M
-8.2%
Price Return 12M
-21.8%
Catalyst Signal
0.00
Market Cap
$1.9B
TTM Revenue
$11.0M
Price / Sales
172.7
ROE
-265.1%
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-15 | C- (1.9) | B+ (3.5) | C (2.2) | B (3.2) | C+ (2.6) | C+ (2.7) |
| 2026-11-08 | F (0.0) | B+ (3.7) | C- (1.9) | B- (3.1) | C+ (2.6) | C (2.3) |
| 2026-11-01 | F (0.0) | B+ (3.6) | C- (1.9) | B (3.2) | C+ (2.7) | C (2.3) |
| 2026-10-25 | F (0.0) | B+ (3.6) | C- (1.9) | B- (3.0) | C+ (2.6) | C (2.2) |
| 2026-10-18 | F (0.0) | B+ (3.6) | C- (1.9) | B- (3.0) | C+ (2.6) | C (2.2) |
Page
1
of
4